What buserelin is
Buserelin is a synthetic peptide with a molecular formula of C60H86N16O13 and a molecular weight of about 1,239 daltons (PubChem CID 50225). It belongs to the class of gonadotropin-releasing hormone (GnRH) agonists, compounds that act on the pituitary gland to regulate the release of reproductive hormones.
Regulatory status
Buserelin has an approved drug label on file, indicating it has gone through formal regulatory review for at least one indication. Specific label details such as approved indications, mechanism text, and brand names were not available in the data used for this monograph, so those sections are omitted here.
What the evidence shows
Buserelin has been studied across 43 registered clinical trials. Several of these trials focus on prostate cancer treatment approaches. One phase 3 trial examined androgen suppression combined with radiation therapy, with or without docetaxel, in patients with high-risk localized prostate cancer, though it was terminated. Another phase 3 trial evaluated radiation therapy with or without androgen-deprivation therapy in prostate cancer patients and reached completion. A related phase 3 study looked at short-term androgen deprivation therapy alongside radiation targeting the prostate and pelvic lymph nodes, though its final status is unknown.
Reported side effects
Side effect report data from the FDA Adverse Event Reporting System (FAERS) was not available for buserelin in this dataset, so no side effect summary is presented here.